scispace - formally typeset
D

Daniel Kidd

Researcher at Janssen Pharmaceutica

Publications -  5
Citations -  802

Daniel Kidd is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Disease & Biomarker (medicine). The author has an hindex of 4, co-authored 5 publications receiving 736 citations.

Papers
More filters
Journal ArticleDOI

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

Niklas Mattsson, +77 more
TL;DR: The cerebrospinal fluid biomarkers amyloid β (Aβ)‐42, total‐Tau (T‐tau), and phosphorylated‐t Tau (P‐tAU) demonstrate good diagnostic accuracy for Alzheimer's disease (AD), but there are large variations in biomarker measurements between studies, and between and within laboratories.
Journal ArticleDOI

CSF biomarker variability in the Alzheimer's Association quality control program

Niklas Mattsson, +118 more
TL;DR: The cerebrospinal fluid biomarkers amyloid beta 1–42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease research and patient management, but there are large variations in biomarker measurements among and within laboratories.
Patent

Oligomeric a.beta. in the diagnosis, prognosis, and monitoring of alzheimer's disease

TL;DR: In this paper, the amounts of combined monomeric and oligomeric Abeta and the ratio can be used in diagnosing, prognosing, and/or monitoring Alzheimer's disease.